Gt biopharma reports fourth quarter and year end 2020 results and business update

Beverly hills, calif., april 19, 2021 /prnewswire/ -- gt biopharma, inc. (nasdaq: gtbp), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the company's proprietary natural killer (nk) cell engager (trike™) protein biologic technology platform, reported financial results for the fourth quarter and year ended december 31, 2020.
GTBP Ratings Summary
GTBP Quant Ranking